Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chlortetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlortetracycline SCHEMBL19787489 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL12356689 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL27323552 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782533 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL16726392 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782583 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3110 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL10901448 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL20952683 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3111 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | PARATEK PHARMACEUTICALS, INC. | 2019-02-07 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARM INNC (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562003-B2 | Methods of using substituted tetracycline compounds to modulate RNA | PARATEK PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | ANTIBODY SYSTEMS, INC. | 2002-06-20 | — | — | US | disclosed |
| US-5098417-A | Cellulosic wound dressing with an active agent ionically absorbed thereon | RICOH KYOSAN, INC. (JP) | 1992-03-24 | — | — | US | disclosed |
| EP-0395476-A2 | Method and apparatus for the production of ionic cloths for use in ionic dressings | RICOH KYOSAN INC. (JP) | 1990-10-31 | — | — | EP | disclosed |
| EP-0338173-A1 | Ionic dressing for topical administration of drugs to wounds and burns | RICOH KYOSAN INC. (JP) | 1989-10-25 | — | — | EP | disclosed |
| US-4684728-A | Solubilizing biologically active compounds with reactive hydrogen atoms | BAYER AKTIENGESELLSCHAFT (DE) | 1987-08-04 | — | — | US | disclosed |
| EP-0014263-B1 | METHOD OF IMPROVING THE SOLUBILITY OF BIOLOGICALLY ACTIVE AGENTS IN WATER AND IN LOWER ALIPHATIC ALCOHOLS, AND COMPOUNDS HAVING AN IMPROVED SOLUBILITY | BAYER AG (DE) | 1982-05-05 | — | — | EP | disclosed |
| US-4324799-A | Fungicidal thioglycolic acid anilides, processes for their manufacture and pesticidal compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-04-13 | — | — | US | disclosed |
| EP-0017772-A1 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| EP-0014263-A2 | Method of improving the solubility of biologically active agents in water and in lower aliphatic alcohols, and compounds having an improved solubility | BAYER AG (DE) | 1980-08-20 | — | — | EP | disclosed |
| US-3980798-A | Dichloromaleic imides for fungicidal composition and method | CIBA-GEIGY CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077276-A1 | Compositions and methods for treating hemorrhagic virus infections and other disorders | IL1R1, TNF, IL1A | MAPT 1669/4885HSD17B10 3400/4885GAA 4525/4885 |
| US-20190040001-A1 | METHODS OF USING SUBSTITUTED TETRACYCLINE COMPOUNDS TO MODULATE RNA | NSUN3, NSUN2, RNMT | MAPT 3193/4885HSD17B10 2912/4885GAA 2673/4885 |
| US-20170305840-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | MYC, TET1, TET3 | MAPT 1743/4885HSD17B10 1591/4885GAA 2782/4885 |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | TET1, TET3, MYC | MAPT 815/4885HSD17B10 2179/4885GAA 2998/4885 |
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | MAPT 823/4885HSD17B10 1112/4885GAA 41/4885 |
| US-20170283368-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | TET3, TET1, DHFR | MAPT 2181/4885HSD17B10 1786/4885GAA 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.